Next Article in Journal
Cytotoxic, Antitumor and Toxicological Profile of Passiflora alata Leaf Extract
Next Article in Special Issue
Structure of a DNA G-Quadruplex Related to Osteoporosis with a G-A Bulge Forming a Pseudo-loop
Previous Article in Journal
Stacking Interactions of Poly Para-Phenylene Vinylene Oligomers with Graphene and Single-Walled Carbon Nanotubes: A Molecular Dynamics Approach
Previous Article in Special Issue
Synthesis and Biological Evaluation of 1,3-Dideazapurine-Like 7-Amino-5-Hydroxymethyl-Benzimidazole Ribonucleoside Analogues as Aminoacyl-tRNA Synthetase Inhibitors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 25
Issue 20
10.3390/molecules25204813
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections

by
Marcella Bassetto
1,
Cecilia M. Cima
2,
Mattia Basso
2,
Martina Salerno
2,
Frank Schwarze
3,
Daniela Friese
3,
Joachim J. Bugert
3 and
Andrea Brancale
2,*
1
Department of Chemistry, Swansea University, Swansea SA2 8PP, UK
2
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
3
Institut für Mikrobiologie der Bundeswehr, 80937 Munich, Germany
*
Author to whom correspondence should be addressed.
Molecules 2020, 25(20), 4813; https://doi.org/10.3390/molecules25204813
Submission received: 26 September 2020 / Revised: 14 October 2020 / Accepted: 16 October 2020 / Published: 20 October 2020
(This article belongs to the Special Issue Advances in Nucleoside/Nucleotides and Nucleic Acid Chemistry: A Theme Issue in Honor of Prof. Dr. Piet Herdewijn)
Browse Figures
Versions Notes

Abstract

:
Previously considered a neglected flavivirus, Zika virus has recently emerged as a public health concern due to its ability to spread rapidly and cause severe neurological disorders, such as microcephaly in newborn babies from infected mothers, and Guillain-Barré syndrome in adults. Despite extensive efforts towards the identification of effective therapies, specific antivirals are still not available. As part of ongoing medicinal chemistry studies to identify new antiviral agents, we screened against Zika virus replication in vitro in a targeted internal library of small-molecule agents, comprising both nucleoside and non-nucleoside agents. Among the compounds evaluated, novel aryloxyphosphoramidate prodrugs of the nucleosides 2′-C-methyl-adenosine, 2-CMA, and 7-deaza-2′C-methyl-adenosine, 7-DMA, were found to significantly inhibit the virus-induced cytopathic effect in multiple relevant cell lines. In addition, one of these prodrugs exhibits a synergistic antiviral effect against Zika virus when applied in combination with an indirect antiviral agent, a l-dideoxy bicyclic pyrimidine nucleoside analogue, which potently inhibits vaccinia and measles viruses in vitro by targeting a host pathway. Our findings provide a solid basis for further development of an antiviral therapy for Zika virus infections, possibly exploiting a dual approach combining two different agents, one targeting the viral polymerase (direct-acting antiviral), the second targeting a host-directed autophagy mechanism.

1. Introduction

Zika virus (ZIKV) belongs to the Flavivirus genus of the Flaviviridae family; it is closely related to other arthropod-borne viruses of the same genus, such as Dengue (DENV), Yellow Fever (YFV), and West Nile (WNV) viruses. First serologically surveyed in Uganda in 1952 [1], it was found in West Africa in 1954 and then spread to Indonesia, Micronesia, Thailand, the Philippines, French Polynesia, and Easter Island-South Pacific [2]. After a first report in Brazil in May 2015, ZIKV has spread rapidly in several countries across the Americas, causing an epidemic which affected more than 850,000 patients [3], and leading the World Health Organisation to declare it a public health emergency of international concern in 2016 [4]. ZIKV is transmitted to humans by mosquitos of the Aedes species, mainly Aedes aegypti and Aedes albopictus [5]. The number of new cases has lately diminished, but the continuous increase in urbanisation and intercontinental travel, and the current climate changes, which are predicted to lead to the adaptation of the main vector Aedes aegypti to new, expanded geographic areas, pose the threat of future outbreaks [6]. ZIKV can also be transmitted through the sexual route, blood transfusions, and the maternal–foetal route [7].
Although usually associated with a self-limiting and mild illness, either asymptomatic or characterised by fever, skin rashes, conjunctivitis, headache, muscle and joint pain, during the recent large outbreaks in French Polynesia and Brazil, different congenital malformations and an enhanced risk of foetal loss have emerged as associated with ZIKV infections during pregnancy [8]. Infections with ZIKV not only cause foetal abnormalities and congenital microcephaly [9], but also a number of neurological complications in adults, such as the Guillain Barré syndrome [8]. This alarming evidence has prompted extensive efforts towards the development of both vaccines and specific therapeutic measures [10], but to date, both options are still unavailable for human use, limiting the treatment of infections to supporting care [11]. As a consequence, the identification of effective antiviral options is highly needed and greatly significant to people’s health worldwide.
The ZIKV replication cycle is closely related to that of other flaviviruses [12], suggesting the potential for antiflaviral agents to display therapeutic activity also in the case of Zika virus. In this context, antiviral nucleoside analogues are a particularly interesting class of compounds, as they currently represent the most important group of antiviral agents, with roughly 50% of all antiviral drugs on the market belonging to this category [13,14]. With few exceptions, these agents exert their mode of action at the viral polymerase level in their triphosphate form. Different prodrug approaches have been developed to aid the metabolic activation of parent nucleosides into their active form, with the McGuigan aryloxyphosphoramidate prodrug (ProTide) technology being the most effective currently available, exploited, among others, in the blockbuster anti-HCV drug sofosbuvir [15]. To date, different nucleoside analogues have shown antiviral effects against ZIKV replication in vitro and in vivo [16], including sofosbuvir itself [17].
In this study, we focused on the in vitro evaluation, using multiple cellular systems relevant to ZIKV replication, of a targeted small library of potential anti-ZIKV agents, focusing on diverse compounds developed in our medicinal chemistry group as potential antivirals for different viruses, including both nucleoside analogues and non-nucleoside small molecules. Within the compounds evaluated in our assays, novel aryloxyphosphoramidate prodrugs of the nucleoside analogues 2′-CMA and 7-DMA were identified as inhibitors of ZIKV-induced cytopathic effect in multiple screening systems, with antiviral EC50 values in the low micromolar range. In addition, one of these prodrugs also displays a synergistic antiviral effect when applied in combination with a previously reported antiviral L-nucleoside analogue, providing a solid basis for the further development of these agents into a viable therapeutic option to treat ZIKV infections.

2. Results and Discussion

2.1. Compound Selection

With the aim to identify novel inhibitors of ZIKV-induced cytopathic effect in cells, we decided to create a focused small library of in-house compounds, prioritising those ones which we had identified, or which we are currently developing, as potential antivirals for related flaviviruses. In particular, we decided to focus our efforts on five structural families in total. Two of these are non-nucleosides, as summarised in Table 1. First, we included 13 diverse structural analogues of 1a (1a–1o): these compounds have been previously identified in our group as potent inhibitors of the replication of hepatitis C virus, which is also a flavivirus [18]. In addition, we screened a second series of 11 non-nucleoside compounds, 2a–2m: 2a has been previously reported as a potent inhibitor of ZIKV replication in Vero cells, with efficacy in reducing ZIKV viremia in vivo in an immunocompetent mouse model, and a mechanism of action pointing towards inhibition of the viral RNA-dependent RNA polymerase (RdRp) [19]. Different structural analogues of 2a, among which we selected 2b–2m, have been recently explored in our research group for their inhibition of human norovirus (hNoV) RdRp, and their ability to interfere with hNoV replication in a replicon system [20].
In parallel, we also tested three diverse structural families of nucleoside analogues. Figure 1 summarises the first two of these families.
Due to the anti-ZIKV activity previously found for 2′-CMA (3a) and 7-DMA [21,22], we prepared a small family of novel aryloxyphosphoramidate prodrugs of these two nucleosides (3b–3d) to evaluate the effect of the application of this prodrug technology [23] on the activity of the parent compounds. In addition, we prepared a series of nucleoside analogues (4b–4o) of the broad-spectrum antiviral agent T-1105 (4a), which has also been reported to inhibit ZIKV replication in cell-based assays, along with its close analogue T-705 (favipiravir), approved in Japan to treat influenza virus infections [24]. As T-1105 and T-705 exert their antiviral activity by inhibiting the viral polymerase after metabolic conversion into their ribofuranosyl 5′-triphosphate forms [24], a small series of ribofuranose analogues of T-1105 and their aryloxyphosphoramidate prodrugs was designed (4c–4i) to modify the sugar part of the nucleoside with the insertion of a 2′-C-methyl substituent, as present in 2′-CMA and 7-DMA, and to introduce the same replacement of the 2′-hydroxy group with a fluorine atom, as present in sofosbuvir. Since the corresponding α-anomers of nucleosides 4c and 4d were obtained during their synthetic preparation (4g, 4h), these were also included in our assays, along with one aryloxyphosphoramidate prodrug of 4h (4i), and the unmodified ribofuranosyl analogue 4b. Finally, as our group is also exploring the antiviral potential of acyclic analogues of T-1105 (unpublished data), acyclic compound 4l was also considered, along with acyclic aryloxyphosphoramidate prodrugs 4m, 4n, and 4o.
Finally, an additional small series of nucleoside-based compounds, 5a–5e, was chosen for evaluation against ZIKV-induced cytopathic effect in our systems (Figure 2).
This small series of l-dideoxy bicyclic pyrimidine nucleoside analogues 5a–5e was included in our evaluation as among them; 5a has been previously found to potently inhibit the replication of both measles and vaccinia viruses in vitro through an indirect mechanism that points towards interference with one or more cellular targets involved with the viral life cycle, thus suggesting its potential effect against other viruses [25]. Although 5a has previously been found to be inactive against the replication of adenovirus and herpes viruses [25], early findings obtained in our group for its potential in inhibiting DENV serotype 2 replication in cell systems (unpublished data) prompted us to prepare a few additional analogues of this compound, and to evaluate them against other flaviviruses, including ZIKV. In particular, our early findings in the case of DENV serotype 2 suggest 5a as an inhibitor of autophagy and micropinocytosis mechanisms, which are relevant to DENV and other flaviviruses [26,27]. This inhibitory effect would likely affect the replication of other flaviviruses, which enter host cells via multiple pathways, including micropinocytosis, as has been demonstrated for ZIKV infections in glioblastoma cells [28].

2.2. Synthetic Chemistry

The preparation of 1a–1o and 2a–2m has recently been reported by our group [17,19], while 3a and 4a are commercially available. T-1105 analogues 4b–4o were prepared according to the synthetic routes summarised in Scheme 1, which also shows the preparation of novel aryloxyphosphoramidates 3b–3d.
Preparation of 4b, the ribofuranosyl form of 4a, has been previously described [29], and was achieved by reacting commercially available 4a with tetra-O-acetyl-β-d-ribofuranose 6, according to a Vorbrüggen coupling procedure [30], which yields acetylated nucleoside 7, then deprotected in a methanolic sodium methoxide solution. Synthesis of both anomers of the 2′-C-methylated derivative, 4c and 4g, has also been previously described [31], and was carried out by coupling in Vorbrüggen conditions 4a with commercial 2-C-methyl-β-d-ribofuranose tetrabenzoate 8. The coupling step of the reaction had to be performed at room temperature, as attempts under reflux conditions or at 50 °C led to the selective formation of the α-anomer only of protected product 9. Performing the coupling step at room temperature allowed the obtainment of both anomers of 9, with an α/β ratio of 2/3. The two anomers were separated after removal of the benzoyl protecting groups in 9, carried out in methanolic ammonia, through a reverse-phase column chromatography purification of the final reaction mixture containing 4c and 4g. 2′-Deoxy-2′-α-fluoro-2′-β-C-methyl analogues 4d and 4h have not been previously described. Their preparation began with the reduction in and subsequent acetylation of commercially available lactone 10, to obtain the acetylated corresponding alcohol 12 in a 1/2 α/β anomeric mixture, following a reported procedure [32]. Coupling of 12 with pseudobase 4a was once again achieved in Vorbrüggen conditions. After chromatographic purification, a 1/1 α/β anomeric mixture was isolated for 13. The two anomers 4d and 4h were separated after removal of the benzoyl protecting groups, which was carried out in methanolic ammonia, through flash column chromatography purification. Additionally, the preparation of novel acyclic analogues 4l and 21 has not been previously reported. Compound 4l was obtained by coupling 4a with (2-acetoxyethoxy)methyl acetate 14 in Vorbrüggen conditions, as previously reported for the synthesis of various acyclic nucleoside analogues [33], followed by deprotection of the residual acetyl group in methanolic ammonia. Preparation of 21 was achieved following the same approach, by coupling 4a with 2-(acetoxymethoxy)propane-1,3-diyl dibenzoate 19 to obtain the protected final intermediate 20, which was treated in methanolic ammonia to achieve the removal of the benzoyl groups in 21. Then, 19 was prepared following a reported three-step synthetic procedure [34], starting from 1,3-dichloropropan-2-ol 16. Finally, novel aryloxyphosphoramide prodrugs 3b–3d, 4e–4f, 4i, 4m, 4n, and 4o were prepared following a coupling reaction between the corresponding nucleoside analogues 3a, commercial 7-DMA, 4c, 4d, 4g, 4h, 4l, and 21 and the appropriate aryl amino acid phosphorochloridate 22 or 23, in the presence of N-methylimidazole (NMI), according to previously validated procedures for the synthesis of ProTide pronucleotides [35]. Then, 22 and 23 were prepared starting from the corresponding ester of L-alanine (either isopropryl or benzyl), and reacting it with phenyl dichlorophosphate, as extensively reported in the literature [35].
Scheme 2 describes the preparation of the final family of tested compounds, 5a–5e.
Preparation of 5a and 5d has been previously described [25], and the reported method was followed also to obtain 5b and 5c. Briefly, commercial carbohydrate 27 was reacted with cyanamide to afford the bicyclic oxazoline 28, which was treated with methyl propiolate in methanol to provide the 2,2′-anhydro-nucleoside 29. Following a bromoacetylation reaction with acetyl bromide in acetonitrile, 29 was converted into nucleoside 30, which was subjected to a reductive β-elimination with activated zinc powder in the presence of glacial acetic acid, to afford 5′-O-acetyl-2′,3′-didehydro-2′,3′-dideoxyuridine 31. The dideoxy nucleoside 32 was then obtained upon catalytic hydrogenation of 31, while preparation of L-5-iodo-2′,3′-dideoxyuridine 33 was achieved after iodination at the C5-position of the nucleobase with iodine in the presence of ammonium cerium(IV) nitrate (CAN), followed by deacetylation with sodium methoxide. A palladium-catalysed Sonogashira coupling of 33 with acetylenes 26 and 34–36 provided the corresponding 5-alkynyl nucleosides, which, after addition of copper (I) iodide in situ with heating, afforded the desired furanopyrimidine products 5a–d, following an intramolecular cyclisation. While 34–36 are commercially available, 26 was prepared in two steps as previously described [29], starting from undec-10-yn-1-ol 24. Preparation of the N-methyl-pyrrolo-pyrimidin-2-one analogue 5e has also been previously described [36], and was obtained from 5a, which was treated with methylamine in methanol while heating, in order to achieve the opening of the fused furane ring by the amine. This was then followed by refluxing the reaction in a higher-boiling solvent mixture after treatment with p-TsCl, to promote a dehydration and cyclisation of the system, with the formation of the target pyrro analogue 5e.

2.3. Antiviral Studies

The selected compounds were first evaluated at a fixed 10 μM concentration for their potential inhibition of ZIKV-induced cytopathic effect in a MTS based TCID50 assay [37], using cell lines which are physiologically relevant for ZIKV infection, including HUH7 hepatoma cells [38], dbtrg cells [28], and A549 cells, which support Zika virus infection in vitro [39]. The cell lines used were chosen to reflect the pathogenesis of ZIKV in liver (HUH7) and CNS tissues (dbtrg), in addition to a cell line where the ZIKV strain originally isolated in Uganda in 1947 grows and forms plaques particularly well (A549). The compounds’ cytotoxicity was also evaluated in the same assay. Ribavirin was used as a positive control [40].
The results of this preliminary assay are summarised in Table 2.
From this evaluation, most of the structural families tested did not show a protective effect against ZIKV-induced cytotoxicity in the cell lines considered. While analogues within the series of compounds 2a–2m and 4a–4o did not show antiviral activity nor relevant cytotoxic effects, several analogues of the first structural scaffold (1a–1o) were found to show some significant cytotoxicity in this assay. Surprisingly and in contrast with what had been previously reported [19], 2a did not show a protective effect against ZIKV-induced cytotoxicity in the cell lines used for our assays. Compounds 3a, 3b–3d, 5a, 5d, and 5e reduced ZIKV-induced cytopathic effect in at least one cell line, showing a significant increase in cell viability in comparison with untreated, infected cells (control-ZIKV), with % values indicating antiviral EC50s in the low micromolar range. The activity observed for 3a is in line with previous literature, which highlights the anti-ZIKV properties of 2′-CMA and 7-DMA [21,22]: as 3b–3d are novel ProTide prodrugs of either one of these two nucleoside analogues, their observed anti-ZIKV effect suggests that application of this pronucleotide technology to 2′-CMA and 7-DMA is associated with an enhanced antiviral effect in comparison with the parent nucleosides. The effect observed for 5a, which is a known indirect antiviral agent [25], and to a lesser extent for 5d and 5e, suggests the very promising potential to explore novel host pathways for the interference with ZIKV life cycle. Due to their protective effect against ZIKV in multiple cell lines, dose–response curves were determined for novel prodrugs 3b–3d and 5a in the HUH7 cell line, as reported in Table 3. Sofosbuvir was included for this evaluation as a positive control. From this analysis, 3c and 3d emerged as the best antiviral hits found in this study, and their antiviral dose–response curves were also determined in the U251 cell line [41], which is an astrocytoma cell line susceptible to ZIKV infection, commonly used as an in vitro model for ZIKV CNS infection.
From this evaluation, 3c in particular emerges as a promising hit molecule for further development, as it shows a low micromolar antiviral effect in both cell lines, and it is associated with the highest selectivity index found in U251 cells, while it retains EC50 values comparable to the ones found for sofosbuvir in our assay.
Finally, we also conducted a preliminary investigation to explore the possibility of combining the effects of an anti-ZIKV nucleoside analogue, which most likely targets the viral polymerase, and of an agent that likely targets a host pathway. For this evaluation, we tested the effect of the combination of 3b and 5a in the A-459 cell line, using an assay that measures cell adherence as an indication of cell viability [42]. Our findings are summarised in Figure 3.
In our assay, cells showed an increase in impedance up to a cell index (CI) of 3.5 in the first 24 h after plating, representing increasing cell–cell contacts and adherence to the well bottom. At this point, the medium was removed (spike; first dotted line in Figure 3) and antiviral compounds were added for a 30-min pretreatment, then ZIKV was added. At the end of the first day of infection (1 day postinfection (dpi)), CI varied, with CI values higher than mock in the combination (light green) and with 5a alone. Virus without compounds (dark green) showed a beginning of loss of impedance, reflecting ZIKV cytopathological effect of cells rounding, with loss of adherence and loss of electrical resistance (impedance). Up to 2 days of infection, the CI values increased, except in the virus control, whereas at 3 dpi (72 h), a significant separation of impedance was observed: the combination curve is similar to the CI value of the uninfected control (mock), indicating full protection. The wells treated with single compounds show less protection with lower CI values. CI value for uninfected cells (mock) remains at the same level until the end of the experiment. All other CI values drop up to 88/96 h postinfection, when the dropping of CI value for the virus only control flattens out, but does not reach a plateau. Relative efficacy of compounds can be determined at any point between 72 and 96 h postinfection. From 72 h postinfection, the effect of the combination of 3b and 5a was more effective than the individual compounds. With the known mechanism of action of the active form of 3b being viral polymerase inhibition, and the mechanism of action of 5a being most likely interference with a host pathway, and with early data found in our lab indicating autophagy inhibition (unpublished results), the observed increased efficacy suggesting synergy. In addition, the calculated EC50 of the 1:1 combination of 3b and 5a in HUH7 cells is 1 ± 0.2 μM, supporting the effects observed on cell impedance/cell-adherence using thexCELLigence RTCA DP instrument.
In conclusion, antiviral evaluation in multiple cell lines of a focused internal library of small-molecule compounds led to the identification of multiple inhibitors of ZIKV-induced cytophatic effect. While we identified three novel ProTide pronucleotides of 2′-CMA and 7-DMA, 3b, 3c, and 3d, as potential leads for the treatment of ZIKV infections, we also found a highly interesting antiviral activity for a l-dideoxy bicyclic pyrimidine nucleoside analogue, 5a, which had been previously reported to potently inhibit the replication of vaccinia and measles viruses in cells, by interfering with a host pathway. In addition to confirming the anti-ZIKV activity of 5a on its own, we also observed a clear synergistic effect for its combination with our ProTide pronucleotide 3b, potentially paving the way for a combination approach for the treatment of ZIKV infection, and also suggesting a novel, host-directed approach for the development of new and improved antiflaviviral strategies. Further exploration of both structural scaffolds and of the synergistic effect observed, along with the elucidation of the precise mechanism of the anti-ZIKV activity of 5a, are currently ongoing.

3. Materials and Methods

3.1. Synthetic Chemistry

3.1.1. General Methodologies

All solvents and reagents were used as obtained from commercial sources unless otherwise indicated. All solvents used for chromatography were HPLC grade from Fisher Scientific (UK). All reactions were performed under a nitrogen atmosphere. 1H, 13C, 19F, and 31P-NMR spectra were recorded with a Bruker Avance III HD spectrometer operating at 500 MHz for 1H and 125 MHz for 13C, with Me4Si as internal standard. Deuterated chloroform was used as the solvent for NMR experiments, unless otherwise stated. 1H chemical shift values (δ) are referenced to the residual non-deuterated components of the NMR solvents (δ = 7.26 ppm for CHCl3, etc.). The 13C chemical shifts (δ) are referenced to CDCl3 (central peak, δ = 77.0 ppm). TLC was performed on silica gel 60 F254 plastic sheets. Normal-phase or reverse-phase automated flash column chromatography was performed using a Biotage Isolera system. UPLC-MS analysis was conducted on a Waters UPLC system with both Diode Array detection and Electrospray (+′ve and −′ve ion) MS detection. The stationary phase was a Waters Acquity UPLC BEH C18 1.7 um 2.1 × 50 mm column. The mobile phase was LC-MS grade H2O containing 0.1% formic acid (A) and LC-MS grade MeCN containing 0.1% formic acid (B). Column temperature: 40 °C. Sample diluent: MeCN or H2O. Sample concentration 1 µg/mL. Injection volume 2 µL. Four alternative methods were used:
-
Linear gradient standard method (A): 90% A (0.1 min); 90–0% A (2.5 min); 0% A (0.3 min); 90% A (0.1 min); flow rate 0.5 mL/min.
-
Linear gradient standard method (B): 90% A (0.1 min); 90–0% A (2.1 min); 0% A (0.8 min); 90% A (0.1 min); flow rate 0.5 mL/min.
-
Linear gradient standard method (C): 90% A (0.1 min); 90–0% A (1.5 min); 0% A (1.4 min); 90% A (0.1 min); flow rate 0.5 mL/min.
-
Linear gradient standard method (D): 99% A (0.1 min); 99–80% A (2.1 min); 0% A (0.8 min); 99% A (0.1 min); flow rate 0.5 mL/min.
High resolution mass spectra (HRMS) were measured in positive mode electrospray ionisation (ES+). All compounds tested in biological assays were >95% pure. Purity of intermediates was >90%, unless otherwise stated. All known intermediates and known compounds were either purchased (3a, 7–DMA, 4a), or prepared according to literature procedures (1a–1o, 2a–2m, 4b, 4c, 4g, 5a, 5d, 5e), with their characterisation data in line with previously reported data. Details for the preparation and full characterisation of novel compounds are given below.

3.1.2. General Method for the Preparation of Novel ProTides 3b–3d, 4e, 4f, 4i, 4m–4o

The appropriate nucleoside 3a, 7–DMA, 4c, 4d, 4g, 4h, 4l, or 21 (1 eq., 0.5 mmol) was suspended in a mixture of anhydrous tetrahydrofuran/pyridine (1:2 v/v, 6 mL) at room temperature under a nitrogen atmosphere. 1-Methylimidazole (6 eq., 3 mmol) was then added dropwise and the mixture was stirred for 20 min. A solution of 23 or 24 (1.5 eq., 0.75 mmol) in anhydrous tetrahydrofuran (4 mL) was then added dropwise and the reaction was stirred at room temperature overnight. The reaction was concentrated under vacuum and the crude residue was purified twice by automated flash column chromatography on silica gel (ethyl acetate to ethyl acetate/methanol 90:10 v/v) to afford the pure title compounds as 1:1 diastereomeric mixtures.

2′-C-Methyladenosine 5′-O-[phenyl-(benzyloxy-l-alaninyl)] Phosphate 3b

Obtained in 36% yield as a white solid. 1H-NMR (CD3OD), δ: 8.24–8.22 (m, 2H), 7.35–7.17 (m, 10H), 6.13, 6.11 (2s, 1H), 5.16–5.02 (m, 2H), 4.57–4.44 (m, 2H), 4.27–4.18 (m, 2H), 4.07–3.99 (m, 1H), 1.35–1.32 (m, 3H), 0.96, 0.93 (2s, 3H). 13C-NMR (CD3OD), δ: 174.80, 174.61, 157.42, 157.41, 154.02, 153.99, 152.19, 152.13, 150.44, 150.37, 140.73, 140.46, 137.24, 137.19, 130.81, 130.78, 129.56, 129.53, 129.35, 129.29, 129.24, 129.13, 128.27, 128.00, 126.15, 121.45, 121.44, 121.42, 121.40, 120.38, 93.37, 93.08, 82.26, 82.06, 80.02, 79.94, 74.46, 73.93, 67.95, 67.89, 67.31, 66.39, 51.77, 51.60, 20.51, 20.26, 20.16. 31P-NMR (202 MHz, CD3OD), δ: 4.01, 3.75. MS [ESI, m/z]: 621.2 [M + Na]. HRMS calculated for C27H32N6O8P+: 599.2019; found 599.2037.

7-Deaza-2′-C-methyladenosine 5′-O-[phenyl-(benzyloxy-l-alaninyl)] Phosphate 3c

Obtained in 40% yield as a white solid. 1H-NMR (CDCl3), δ: 8.28 (s, 1H), 7.39–7.28 (m, 7H), 7.24–7.22 (m, 2H), 7.15–7.03 (m, 2H), 6.39–6.29 (m, 2H), 5.68 (bs, 1H), 5.62 (bs, 1H), 5.38, 5.31 (2s, 2H), 4.54–4.42 (m, 2H), 4.23–4.21 (m, 1H), 4.14–4.01 (m, 2H), 3.45–3.39, 3.06–2.98 (2m, 1H), 1.37–1.31 (m, 3H), 0.82 (s, 3H). 13C-NMR (CDCl3), δ: 176.60, 173.48, 173.42, 156.57, 156.55, 150.66, 150.58, 149.68, 149.55, 135.19, 135.17, 129.79, 129.78, 128.63, 128.62, 128.49, 128.47, 128.20, 128.16, 125.13, 125.03, 122.17, 122.00, 120.16, 120.09, 99.21, 99.15, 91.44, 91.26, 81.13, 81.00, 78.97, 74.11, 73.79, 67.28, 65.92, 52.84, 50.44, 50.31, 29.70, 20.79, 20.05. 31P-NMR (202 MHz, CDCl3), δ: 3.21, 2.69. UPLC-MS (Method B): Rt 1.68 min, MS [ESI, m/z]: 598.3 [M + H]. HRMS calculated for C28H33N5O8P+: 598.2061; found 598.2073.

7-Deaza-2′-C-methyladenosine 5′-O-[phenyl-(isopropoxy-l-alaninyl)] Phosphate 3d

Obtained in 46% yield as a colourless waxy solid. 1H-NMR (CDCl3), δ: 8.19 (s, 1H), 7.22–7.13 (m, 4H), 7.05–6.93 (m, 2H), 6.32–6.22 (m, 2H), 5.81 (bs, 1H), 5.77 (bs, 1H), 4.93–4.83 (m, 1H), 4.62–4.32 (m, 3H), 4.18–4.12 (m, 1H), 3.98–3.89 (m, 2H), 1.26, 1.25 (2 s, 3H), 1.12–1.04 (m, 6H,), 0.71, 0.69 (2s, 3H). 13C-NMR (CDCl3), δ: 173.24, 173.19, 173.14, 156.91, 156.89, 151.55, 151.48, 150.71, 150.66, 149.69, 149.58, 129.75, 125.04, 124.97, 121.84, 121.71, 120.13, 120.11, 120.09, 120.07, 103.43, 103.35, 99.16, 91.43, 91.27, 80.70, 80.64, 73.93, 73.58, 69.34, 69.28, 65.89, 65.85, 65.26, 65.23, 50.48, 50.36, 21.65, 21.57, 20.93, 20.89, 20.84, 20.80, 19.89, 19.86. 31P-NMR (202 MHz, CDCl3), δ: 3.38, 3.11. MS [ESI, m/z]: 550.2 [M + H], 572.2 [M + Na]. HRMS calculated for C24H33N5O8P+: 550.2061; found 550.2049.

4-(2′-C-Methyl-β-d-ribofuranosyl)-3-oxo-3,4-dihydropyrazine-2-carboxamide 5′-O-[phenyl-(benzyloxy-l-alaninyl)] Phosphate 4e

Obtained in 48% yield as a pale yellow waxy solid. 1H-NMR (CDCl3), δ: 9.04 (bs, 1H), 7.86 (bs, 1H), 7.72–7.65 (m, 1H), 7.38–7.31 (m, 8H), 7.24–7.15 (m, 3H), 6.28–6.19 (m, 2H), 5.16, 5.15 (2s, 2H), 4.53–4.46 (m, 1H), 4.40–4.35 (m, 1H), 4.23–4.19 (m, 1H), 4.10–4.03 (m, 1H), 3.87 (d, J = 7.5 Hz, 1H), 3.75 (bs, 2H), 1.42–1.38 (m, 3H), 0.97, 0.96 (2s, 3H). 13C-NMR (CDCl3), δ: 175.66, 168.82, 164.78, 163.92, 157.46, 150.42, 143.64, 135.04, 129.93, 128.70, 128.62, 128.61, 128.24, 128.14, 127.42, 127.21, 125.43, 125.38, 119.98, 119.89, 99.98, 92.40, 90.00, 89.69, 81.63, 80.03, 75.27, 73.18, 72.92, 67.49, 64.49, 50.54, 50.41, 20.82, 20.78, 20.63, 20.61.31P-NMR (202 MHz, CDCl3), δ: 3.60, 3.19. UPLC-MS (Method B): Rt 1.71 min, MS [ESI, m/z]: 625.2 [M + Na]. HRMS calculated for C27H32N4O10P+: 603.1851; found 603.1839.

4-[(2’-R)-2’-C-Deoxy-2’-C-fluoro-2′-C-methyl-β-d-ribofuranosyl]-3-oxo-3,4-dihydropyrazine-2-carboxamide 5′-O-[phenyl-(benzyloxy-l-alaninyl)] Phosphate 4f

Obtained in 55% yield as a white glassy solid. 1H-NMR (CDCl3), δ: 9.17–9.12 (bs, 1H), 7.75–7.64 (m, 1H), 7.59–7.50 (m, 1H), 7.40–7.31 (m, 7H), 7.25–7.18 (m, 3H), 6.52, 6.47 (2d, JF = 18.2 Hz, 1H), 6.27 (bs, 1H), 5.18–5.16 (m, 2H), 4.63–4.55 (m, 1H), 4.51–4.46 (m, 1H), 4.24–4.07 (m, 3H), 4.01, 3.96 (2d, J = 8.9 Hz, 1H), 3.85–3.74 (m, 1H), 1.45–1.42 (m, 3H), 1.35–1.30 (m, 3H). 13C-NMR (CDCl3), δ: 173.87, 173.52, 163.21, 163.12, 155.40, 155.31, 150.43, 150.38, 143.94, 143.74, 134.98, 134.93, 130.05, 130.01, 128.72, 128.60, 126.89, 126.43, 125.58, 125.36, 120.61, 120.57, 119.69, 119.08, 101.18, 101.11, 99.70, 99.63, 89.38, 89.08, 80.34, 80.09, 70.83, 70.71, 67.57, 67.50, 63.57, 63.42, 50.61, 50.39, 30.19, 29.71, 20.82, 20.67, 16.59, 16.39. 19F-NMR (470 MHz, CDCl3), δ: −163.21, −163.32. 31P-NMR (202 MHz, CDCl3), δ: 4.26, 3.52. UPLC-MS (Method B): Rt 1.80 min (diast. 1), 1.82 min (diast. 2), MS [ESI, m/z]: 605.2 [M + H]. HRMS calculated for C27H31FN4O9P+: 605.1807; found 605.1831.

4-[(2’-R)-2’-C-Deoxy-2’-C-fluoro-2′-C-methyl-α -d-ribofuranosyl]-3-oxo-3,4-dihydropyrazine-2-carboxamide 5′-O-[phenyl-(benzyloxy-l-alaninyl)] Phosphate 4i

Obtained in 57% yield as a white glassy solid. 1H-NMR (CDCl3), δ: 9.04, 9.02 (2d, J = 3.1 Hz, 1H), 7.72 (app. d, J = 4.2 Hz, 1H), 7.50–7.48 (m, 1H), 7.38–7.30 (m, 7 H), 7.24–7.15 (m, 3H), 6.38, 6.27 (2d, JF = 19.2 Hz, 1H), 6.28–6.14 (m, 1H), 5.19 (d, J = 5.7 Hz, 1H), 5.14 (s, 1H), 4.42–4.25 (m, 4H), 4.23–4.03 (m, 2H), 3.92–3.80 (m, 1H), 1.55, 1.42 (2d, JF = 22.5 Hz, 3H), 1.41–1.36 (m, 3H). 13C-NMR (CDCl3), δ: 173.87, 173.40, 163.10, 155.55, 150.45, 150.33, 143.69, 143.58, 135.14, 135.06, 129.92, 129.86, 128.71, 128.69, 128.62, 128.55, 128.23, 127.93, 125.58, 125.35, 124.40, 124.33, 120.61, 120.16, 100.07, 99.93, 98.54, 98.40, 87.46, 87.32, 81.78, 81.66, 73.70, 73.56, 67.49, 67.39, 64.85, 64.25, 50.49, 50.30, 20.83, 20.62, 17.74, 17.54. 19F-NMR (470 MHz, CDCl3), δ: −176.77, −176.84. 31P-NMR (202 MHz, CDCl3), δ: 3.68, 2.94. UPLC-MS (Method B): Rt 1.77 min, MS [ESI, m/z]: 605.2 [M + H]. HRMS calculated for C27H31FN4O9P+: 605.1807; found 605.1795.

Benzyl ((2-((3-carbamoyl-2-oxopyrazin-1(2H)-yl)methoxy)ethoxy)(phenoxy)phosphoryl)-l-alaninate 4m

Obtained in 51% yield as a pale yellow oil. 1H-NMR (CDCl3), δ: 9.07 (bs, 1H), 7.69, 7.68 (2d, J = 4.1 Hz, 1H), 7.53, 7.48 (2d, J = 4.1 Hz, 1H), 7.37–7.29 (m, 7H), 7.21–7.14 (m, 3H), 6.24 (bs, 1H), 5.40 (d, J = 2.5 Hz, 1H), 5.35 (d, J = 5.3 Hz, 1H), 5.16 (s, 1H), 5.13 (s, 1H), 4.27–4.16 (m, 2H), 4.14–4.02 (m, 1H), 3.86–3.76 (m, 2H), 3.75–3.69 (m, 1H), 1.40, 1.38 (2d, J = 7.1 Hz, 3H). 13C-NMR (CDCl3), δ: 173.48, 173.41, 173.34, 162.98, 155.94, 155.92, 150.66, 150.63, 144.85, 144.81, 135.24, 135.21, 130.01, 129.97, 129.73, 129.71, 128.68, 128.66, 128.58, 128.53, 128.23, 128.19, 125.06, 124.87, 124.86, 120.22, 120.18, 120.12, 120.08, 77.90, 69.72, 69.67, 67.29, 67.27, 65.65, 65.61, 50.41, 50.31, 20.95, 20.91. 31P-NMR (202 MHz, CDCl3), δ: 2.68, 2.36. UPLC-MS (Method B): Rt 1.81 min, MS [ESI, m/z]: 553.2 [M + Na]. HRMS calculated for C24H28N4O8P+: 531.1639; found 531.1645.

Isopropyl ((2-((3-carbamoyl-2-oxopyrazin-1(2H)-yl)methoxy)ethoxy)(phenoxy) phosphoryl)-l-alaninate 4n

Obtained in 55% yield as an off-white waxy solid. 1H-NMR (CDCl3), δ: 9.11 (bs, 1H), 7.72 (d, J = 4.1 Hz, 1H), 7.57, 7.55 (2d, J = 4.1 Hz, 1H), 7.34–7.30 (m, 2H), 7.22–7.14 (m, 3H), 6.03 (bs, 1H), 5.43 (d, J = 2.4 Hz, 1H), 5.41 (d, J = 4.5 Hz, 1H), 5.02–4.96 (m, 1H), 4.30–4.23 (m, 2H), 4.03–3.92 (m, 1H), 3.88–3.83 (m, 1H), 3.61–3.52 (m, 1H), 1.37–1.34 (2d, J = 6.9 Hz, 3H), 1.24–1.20 (m, 6H). 13C-NMR (CDCl3), δ: 173.51, 173.45, 173.30, 162.89, 155.90, 155.88, 150.59, 150.55, 144.90, 144.85, 130.01, 129.76, 129.74, 125.09, 124.98, 120.23, 120.19, 120.16, 120.12, 77.92, 69.80, 69.75, 69.42, 53.47, 50.40, 50.33, 21.72, 21.64, 21.09. 31P-NMR (202 MHz, CDCl3), δ: 2.80, 2.55. UPLC-MS (Method B): Rt 1.66 min, MS [ESI, m/z]: 505.2 [M + Na]. HRMS calculated for C20H28N4O8P+: 483.1639; found 483.1651.

Benzyl ((2-((3-carbamoyl-2-oxopyrazin-1(2H)-yl)methoxy)-3-hydroxypropoxy)(phenoxy) phosphoryl)-l-alaninate 4o

Obtained in 54% yield as a pale yellow solid. 1H-NMR (CDCl3), δ: 9.01 (bs, 1H), 7.65–7.61 (m, 2H), 7.32–7.27 (m, 7H), 7.17–7.10 (m, 3H), 6.60 (bs, 1H), 5.51–5.43 (m, 1H), 5.41–5.32 (m, 1H), 5.12, 5.09 (2s, 2H), 4.23–4.04 (m, 2H), 4.02–3.87 (m, 2H), 3.70-–3.52 (m, 2H), 1.37–1.34 (m, 3H). 13C-NMR (CDCl3), δ: 173.58, 173.45, 163.58, 155.89, 150.54, 144.13, 135.22, 131.43, 129.76, 129.73, 128.68, 128.64, 128.56, 128.50, 128.21, 128.15, 127.87, 125.13, 124.73, 120.27, 120.23, 120.17, 120.14, 120.11, 79.83, 77.76, 67.27, 66.01, 61.17, 61.10, 50.42, 50.30, 20.79, 20.76. 31P-NMR (202 MHz, CDCl3), δ: 3.34, 2.98. UPLC-MS (Method B): Rt 1.74 min, MS [ESI, m/z]: 583.2 [M + Na]. HRMS calculated for C25H30N4O9P+: 561.1745; found 561.1763.

3.1.3. Preparation of Novel 2′-Deoxy-2′-α-fluoro-2′-β-C-methyl-ribofuranosyl Analogues 4d and 4h

Commercially available 4a (20 mmol, 1.5 eq.) was suspended in anhydrous MeCN (50 mL) under a nitrogen atmosphere. N,O-Bis(trimethylsilyl)acetamide (BSA, 40 mmol, 3 eq.) was then added, and the mixture was stirred under reflux for 1 h. The resulting solution was then cooled to room temperature, and acetylated alcohol 12, obtained in a 1/2 α/β anomeric mixture according to a previously reported procedure [32] (13.5 mmol, 1 eq.), was dissolved in anhydrous MeCN (10 mL) and added to the reaction mixture. Finally, the mixture was cooled in an ice-bath and SnCl4 (47 mmol, 3.5 eq.) was slowly added. The reaction was allowed to warm to room temperature and then heated to 50 °C for 24 h. The mixture was then cooled to 0 °C and a cold saturated NaHCO3 solution (100 mL) was added slowly while stirring. The residue was then extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with water and brine, dried over Na2SO4, and concentrated under vacuum. The crude residue was purified twice by automated flash column chromatography on silica gel (ethyl acetate to ethyl acetate/methanol 90:10 v/v) to afford 13 as a 1/1 α/β anomeric mixture (pale yellow solid, 75%). Compound 13 (1 mmol, 1 eq.) was then added to 7N methanolic ammonia (15 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was then dried under vacuum and the crude residue was purified three times by automated flash column chromatography on silica gel (dichloromethane to dichloromethane/methanol 90:10 v/v) to afford the pure nucleosides 4d and 4h.

4-[(2’-R)-2’-C-Deoxy-2’-C-fluoro-2′-C-methyl-β-D-ribofuranosyl]-3-oxo-3,4-dihydropyrazine-2-carboxamide 4d

Obtained in 25% yield as a pale yellow solid. 1H-NMR (DMSO-d6), δ: 8.24 (d, J = 4.4 Hz, 1H), 8.23 (bs, 1H), 7.75 (bs, 1H), 7.56 (d, J = 4.4 Hz, 1H), 6.29 (d, JF = 18.3 Hz, 1H), 5.74 (d, J = 6.7 Hz, 1H), 5.43 (app. t, J = 4.5 Hz, 1H), 3.97–3.87 (m, 3H), 3.70 (ddd, J1 = 11.7 Hz, J2 = 3.7 Hz, J3 = 1.8 Hz, 1H), 1.21 (d, JF = 22.5 Hz, 3H). 13C-NMR (DMSO-d6), δ: 164.58, 154.23, 148.66, 126.66, 123.60, 101.59 (d, JF = 182.3 Hz), 82.65, 70.31 (d, JF = 17.1 Hz), 58.57, 49.07, 16.87 (d, JF = 24.9 Hz). 19F-NMR (470 MHz, DMSO-d6), δ: −161.20. UPLC-MS (Method D): Rt 1.59 min, MS [ESI, m/z]: 288.2 [M + H]. HRMS calculated for C11H15FN3O5+: 288.0990; found 288.0976.

4-[(2’-R)-2’-C-Deoxy-2’-C-fluoro-2′-C-methyl-α-D-ribofuranosyl]-3-oxo-3,4-dihydropyrazine-2-carboxamide 4h

Obtained in 46% yield as a white solid. 1H-NMR (DMSO-d6), δ: 8.21 (bs, 1H), 7.74–7.69 (m, 2H), 7.51 (d, J = 4.4 Hz, 1H), 6.38 (d, JF = 19.2 Hz, 1H), 5.78 (d, J = 7.2 Hz, 1H), 4.90 (app. t, J = 5.5 Hz, 1H), 4.21–4.18 (m, 1H), 4.06–4.01 (m, 1H), 3.75 (dd, J1 = 12.1 Hz, J2 = 3.5 Hz, 1H), 3.57–3.51 (m, 1H), 1.45 (d, JF = 22.4 Hz, 3H). 13C-NMR (DMSO-d6), δ: 164.83, 154.18, 148.77, 128.52, 122.75, 99.64 (d, JF = 191.2 Hz), 87.25 (d, JF = 14.5 Hz), 84.08, 73.21 (d, JF = 17.2 Hz), 60.68, 18.23 (d, JF = 25.1 Hz). 19F-NMR (470 MHz, DMSO-d6), δ: −174.08. UPLC-MS (Method D): Rt 0.61 min, MS [ESI, m/z]: 310.1 [M + Na]. HRMS calculated for C11H15FN3O5+: 288.0990; found 288.0998.

3.1.4. Preparation of 4-((2-Hydroxyethoxy)methyl)-3-oxo-3,4-dihydropyrazine-2-carboxamide 4l

Commercially available 4a (3.6 mmol, 1 eq.) was suspended in anhydrous MeCN (10 mL) under a nitrogen atmosphere. N,O-Bis(trimethylsilyl)acetamide (BSA, 8.3 mmol, 2.3 eq.) was then added, and the mixture was stirred under reflux for 1 h. The resulting solution was then cooled to room temperature, and commercially available (2-acetoxyethoxy)methyl acetate 14 was added (3.6 mmol, 1 eq.). The mixture was then cooled in an ice-bath and SnCl4 (8.3 mmol, 2.3 eq.) was slowly added. The reaction was allowed to warm to room temperature and stirred overnight. The mixture was then cooled to 0 °C, and a cold saturated NaHCO3 solution (40 mL) was added slowly while stirring. The residue was then extracted with EtOAc (5 × 50 mL). The combined organic layers were washed with water and brine, dried over Na2SO4, and concentrated under vacuum. The crude residue was purified by automated flash column chromatography on silica gel (dichloromethane to dichloromethane/methanol 90:10 v/v) to afford 15 as a yellow oil (81%). Compound 15 (2.5 mmol, 1 eq.) was then dissolved in MeOH (10 mL) and the solution was cooled to 0 °C in an ice-bath. A 25% MeONa solution in MeOH (0.9 mL, 1.5 eq.) was added and the reaction was stirred for 40 min at 0 °C. Glacial acetic acid (3.6 mL) was then added dropwise to the reaction while stirring, and the mixture was dried under vacuum. The crude residue was purified twice by automated flash column chromatography on silica gel (ethyl acetate to ethyl acetate/methanol 85:15 v/v) to afford the pure title compound 4l as a pale yellow oil in 78% yield. 1H-NMR (CD3OD), δ: 7.97 (d, J = 3.7 Hz, 1H), 7.70 (d, J = 3.7 Hz, 1H), 5.53 (s, 2H), 3.73–3.70 (m, 4H). 13C-NMR (CD3OD), δ: 164.89, 156.04, 145.05, 132.14, 123.73, 78.32, 71.97, 60.51. UPLC-MS (Method D): Rt 0.65 min, MS [ESI, m/z]: 236.1 [M + Na]. HRMS calculated for C8H12N3O4+: 214.0822; found 214.0810.

3.1.5. Preparation of 4-(((1,3-Dihydroxypropan-2-yl)oxy)methyl)-3-oxo-3,4-dihydropyrazine-2-carboxamide 21

Commercially available 4a (3.6 mmol, 1 eq.) was suspended in anhydrous MeCN (9 mL) under a nitrogen atmosphere. N,O-Bis(trimethylsilyl)acetamide (BSA, 8.3 mmol, 2.3 eq.) was then added, and the mixture was stirred under reflux for 1 h. The resulting solution was cooled to room temperature, and 2-(acetoxymethoxy)propane-1,3-diyl dibenzoate 19 (3.6 mmol, 1 eq.), prepared following a reported procedure [34], was added dissolved in MeCN (3 mL). The mixture was then cooled in an ice-bath, and SnCl4 (8.3 mmol, 2.3 eq.) was slowly added. The reaction was allowed to warm to room temperature and stirred overnight. The mixture was then cooled to 0 °C and a cold saturated NaHCO3 solution (40 mL) was added slowly while stirring. The residue was then extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with water and brine, dried over Na2SO4 and concentrated under vacuum. The crude residue was purified by automated flash column chromatography on silica gel (dichloromethane to dichloromethane/methanol 90:10 v/v) to afford 20 as an orange oil (80%). Compound 20 (2.8 mmol, 1 eq.) was then added to 7N methanolic ammonia (40 mL), and the mixture was stirred at room temperature overnight. The reaction mixture was then dried under vacuum, and the crude residue was purified by automated flash column chromatography on silica gel (chloroform to chloroform/methanol 80:20 v/v) to afford the pure title compound 21 as a pale yellow solid in 69% yield. 1H-NMR (DMSO-d6), δ: 8.38 (bs, 1H), 7.96 (d, J = 4.1 Hz, 1H), 7.73 (bs, 1H), 7.53 (d, J = 4.1 Hz, 1H), 5.46 (s, 2H), 4.69 (t, J = 5.5 Hz, 2H), 3.61–3.57 (m, 1H), 3.49–3.45 (m, 2H), 3.40–3.36 (m, 2H). 13C-NMR (DMSO-d6), δ: 164.48, 155.00, 147.96, 131.63, 123.08, 82.40, 77.34, 61.37. UPLC-MS (Method D): Rt 0.36 min, MS [ESI, m/z]: 266.1 [M + Na]. HRMS calculated for C9H14N3O5+: 244.0928; found 244.0941.

3.1.6. General Procedure for the Preparation of Novel 3-(2′,3′-Dideoxy-ribo-β-l-furanosyl)-6-substituted-furo[2,3d]pyrimidin-2-(3H)one Analogues 5b and 5c

l-5-iodo-2′,3′-dideoxyuridine 33 (0.35 mmol, 1 eq.), prepared as previously described [25], was dissolved in anhydrous DMF (2 mL) under a nitrogen atmosphere. The appropriate alkyne 34 or 35 (1.05 mmol, 3 eq.) was then added, followed by tetrakis(triphenylphosphine)palladium (0.03 mmol, 0.1 eq.), CuI (0.07 mmol, 0.2 eq.), and DIPEA (0.7 mmol, 2 eq.). The resulting mixture was stirred at room temperature for 18 h. At this point, further CuI (0.07 mmol, 0.2 eq.) and Et3N (2 mL) were added, and the mixture was stirred at 80 °C for 8 h. The residue was dried under vacuum by co-evaporation with EtOAc, and the crude product was purified by automated flash column chromatography on silica gel (dichloromethane to dichloromethane/methanol 92:8 v/v) to afford the pure target compounds 5b and 5c.

3-(2′,3′-Dideoxy-ribo-β-l-furanosyl)-6-(1-nonanol) furo[2,3-d]pyrimidin- 2(3H)-one 5b

Obtained in 28% yield as an off-white solid. 1H-NMR (CDCl3), δ: 8.66 (s, 1H), 6.22 (dd, J1 = 4.1 Hz, J2 = 2.5 Hz, 1H), 6.13 (d, J = 7.5 Hz, 1H), 4.31 (m, 1H), 4.04−4.01 (m, 1H), 3.79 (1H, dt, J1 = 12.1 Hz, J2 = 4.2 Hz, 1H), 3.66 (m, 2H), 2.68–2.60 (m, 3H), 2.26–2.21 (m, 1H), 2.17 (t, J = 4.5Hz, 1H), 1.98−1.91 (m, 2H), 1.73–1.67 (m, 2H), 1.59–1.55 (m, 2H), 1.41−1.32 (m, 11H). 13C-NMR (CDCl3), δ: 171.57, 159.75, 155.50, 137.21, 107.64, 99.29, 88.15, 83.55, 61.64, 61,59, 33.33, 32.23, 29.16, 29.10, 28.88, 28.64, 27.54, 26.61, 25.50, 23.31. MS [ESI, m/z]: 379.2 [M + H]. HRMS calculated for C20H31N2O5+: 379.2227; found 379.2209.

3-(2′,3′-Dideoxy-ribo-β-l-furanosyl)-6-(n-butil)furo[2,3-d]pyrimidin- 2(3H)-one 5c

Obtained in 33% yield as a pale yellow solid. 1H-NMR (CDCl3), δ: 8.68 (s, 1H), 6.21 (d, J = 4.5 Hz, 1H), 6.14 (s, 1H), 4.31 (m, 1H), 4.16 (d, J = 11.5 Hz, 1H), 3.89 (d, J = 11.5 Hz, 1H), 2.68−2.61 (m, 3H), 2.33 (bs, 1H), 2.24−2.21 (m, 1H),1.97−1.93 (m, 2H),1.69 (m, 1H), 1.41−1.31 (m, 2H), 1.28(m, 1H), 0.91 (t, J = 7.2 Hz, 3H). 13C-NMR (CDCl3), δ: 171.72, 159.46, 155.02, 135.89, 107.24, 99.08, 88.99, 82.88, 62.85, 33.78, 28.87, 27.94, 23.89, 22.11, 13.70. MS [ESI, m/z]: 293.1 [M + H]. HRMS calculated for C15H21N2O4+: 293.1496; found 293.1510.

3.2. Antiviral Studies

3.2.1. Antivirals

Lyophilized compounds were solubilized in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to a stock concentration of 10 mM and kept frozen at −20 °C and then were diluted to final assay concentrations. Dissolved compounds were stored at −20 °C and brought to room temperature prior to assay. All compounds were well dissolved in DMSO, and precipitates were not observed upon thawing.

3.2.2. Cell Culture

The human hepatoma cell line HUH7 was a gift of Ralf Bartenschlager, University of Heidelberg. Human glioblastoma cell lines U138 and U251 were originally obtained from the American Tissue Type Culture collection (ATCC) and European Collection of Authenticated Cell Cultures (ECACC)—with the numbers U138 MG—ATCC® HTB16™, U251MG ECACC catalogue number 09063001, respectively. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 mg/mL glucose (Gibco Life Technologies Thermo Fisher, Waltham, MA, USA) supplemented with 10% (v/v) heat inactivated fetal bovine serum (FBS; Gibco Life Technologies) at 37 °C with 5% CO2 (DMEM/FC10).

3.2.3. Virus Culture

ZIKV-U (976 Uganda strain; isolated from a non-human primate in Uganda in 1947; strain form the Stammsammlung (strain bank) of the Institut für Mikrobiologie der Bundeswehr) was grown to high titer on Vero B4 cells, partially purified by centrifugation to remove cell debris and stored frozen at −80 °C. Virus titer was determined by standard plaque assay.

3.2.4. Viability Assay

Cell viability was determined after seven days using CellTiter-Glo® (PROMEGA), (Madison, WI, USA) following the manufacturer’s instructions. All experiments were performed in triplicate. Briefly, cells were seeded into white 96 well plates (Greiner-Bio ONE; Kremsmünster, Austria) at a density of 104 cells per well in a volume of 100 µL DMEM/FC10, then incubated for 16 h. Cells were treated in triplicates with the antiviral compound, prediluted to a range of concentrations, and added in a volume of 50 µL DMEM, then immediately infected with ZIKV-U or DENV2, prediluted and added in a volume of 50 µL DMEM, at a multiplicity of infection of 0.3 to the final antiviral concentration in 200 µL final assay volume. Uninfected/untreated controls were prepared in multiple triplicates in different locations on the 96 well plate. Cells were incubated for 4 days at 37 °C with 5% CO2. The reconstituted CellTiter-Glo® reagent was then added to the cells and luminescence was detected within 60 min by the Victor X3 2030 Multilabel Reader (PerkinElmer, Waltham, MA, USA) according to the manufacturer’s instructions. Data were analysed using Microsoft EXCEL and Graphpad PRISM 7.0 software.

3.2.5. Cell Adherence Assay

Cell adherence was determined using the xCELLigence assay in the 16 well format [42]. Briefly, cells were plated at a density of 104 cells per well in a 16 well CIM-Plate 16 for the xCELLigence RTCA DP Instrument (ACEA Biosciences, Inc., San Diego, CA, USA). After plating, cells were observed for one hour to confirm adherence and impedance. The monitoring was then suspended for a 30-min pretreatment with compounds followed by infection with virus, after which monitoring was resumed. The instrument recorded impedance over time in each well. The data shown represent averages of duplicates. Data were analysed using the xCELLigence Real-Time Cell Analyzer (RTCA) software.

Author Contributions

Conceptualization, M.B. (Marcella Bassetto), A.B. and J.J.B.; methodology, M.B. (Marcella Bassetto), C.M.C., M.B. (Mattia Basso), M.S., F.S. and D.F.; formal analysis, M.B. (Marcella Bassetto) and J.J.B.; investigation, M.B. (Marcella Bassetto), A.B. and J.J.B.; resources, M.B. (Marcella Bassetto), A.B. and J.J.B.; data curation, M.B. (Marcella Bassetto) and J.J.B.; writing—original draft preparation, M.B. (Marcella Bassetto); writing—review and editing, M.B. (Marcella Bassetto), A.B. and J.J.B.; supervision, M.B. (Marcella Bassetto), A.B. and J.J.B.; project administration, M.B. (Marcella Bassetto) and J.J.B.; funding acquisition, M.B. (Marcella Bassetto), A.B. and J.J.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Sêr Cymru II programme, part-funded by Cardiff University and the European Regional Development Fund through the Welsh Government.

Acknowledgments

The authors would like to thank Ralf Bartenschlager, University of Heidelberg, for kindly providing the human hepatoma cell line HUH7.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Dick, G.W. Zika virus. II. Pathogenicity and physical properties. Trans. R. Soc. Trop. Med. Hyg. 1952, 46, 521–534. [Google Scholar] [CrossRef]
  2. Ferraris, P.; Yssel, H.; Missé, D. Zika virus infection: An update. Microbes Infect. 2019, 19, 30052–30058. [Google Scholar] [CrossRef] [PubMed]
  3. Musso, D.; Ko, A.I.; Baud, D. Zika virus infection—After the pandemic. N. Engl. J. Med. 2019, 381, 1444–1457. [Google Scholar] [CrossRef]
  4. WHO. Zika: The continuing threat. Bull. World Health Organ. 2019, 97, 6–7. [Google Scholar] [CrossRef] [PubMed]
  5. Song, B.-H.; Yun, S.-I.; Woolley, M.; Lee, M.-L. Zika virus: History, epidemiology, transmission, and clinical presentation. J. Neuroimmunol. 2017, 380, 50–64. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Ryan, S.J.; Carlson, C.J.; Mordecai, E.A.; Johnson, L.R. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Negl. Trop. Dis. 2019, 13, e0007213. [Google Scholar] [CrossRef] [Green Version]
  7. Rasmussen, S.A.; Jamieson, D.J.; Honein, M.A.; Petersen, L.R. Zika virus and birth defects—Reviewing the evidence for causality. N. Engl. J. Med. 2016, 374, 1981–1987. [Google Scholar] [CrossRef]
  8. Krauer, F.; Riesen, M.; Reveiz, L.; Oladapo, O.T.; Martínez-Vega, R.; Porgo, T.V.; Haefliger, A.; Broutet, N.J.; Low, N. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: Systematic review. PLoS Med. 2017, 14, e1002203. [Google Scholar] [CrossRef] [Green Version]
  9. Broutet, N.; Krauer, F.; Riesen, M.; Khalakdina, A.; Almiron, M.; Aldighieri, S.; Espinal, M.; Low, N.; Dye, C. Zika Virus as a Cause of Neurologic Disorders. N. Engl. J. Med. 2016, 374, 1506–1509. [Google Scholar] [CrossRef] [Green Version]
  10. Masmejan, S.; Baud, D.; Musso, D.; Panchaud, A. Zika virus, vaccines, and antiviral strategies. Expert Rev. Anti-Infect. Ther. 2018, 16, 471–483. [Google Scholar] [CrossRef]
  11. Duarte, G.; Moron, A.; Timerman, A.; Fernandes, C.; Mariani Neto, C.; Almeida Filho, G.; Werner Junior, H.; Espírito Santo, H.; Steibel, J.; Bortoletti Filho, J.; et al. Zika virus infection in pregnant women and microcephaly. Rev. Bras. Ginecol. Obstet. RBGO Gynecol. Obstet. 2017, 39, 235–248. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Chong, H.Y.; Leow, C.Y.; Abdul Majeed, A.B.; Leow, C.H. Flavivirus infection—A review of immunopathogenesis, immunological response, and immunodiagnosis. Virus Res. 2019, 274, a197770. [Google Scholar] [CrossRef] [PubMed]
  13. Seley-Radtke, K.L.; Yates, M.K. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antivir. Res. 2018, 154, 66–86. [Google Scholar] [CrossRef] [PubMed]
  14. Yates, M.K.; Seley-Radtke, K.L. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antivir. Res. 2019, 162, 5–21. [Google Scholar] [CrossRef]
  15. Mehellou, Y.; Rattan, H.S.; Balzarini, J. The ProTide prodrug technology: From the concept to the clinic. J. Med. Chem. 2018, 61, 2211–2226. [Google Scholar] [CrossRef]
  16. Del Sarto, J.L.; Rocha, R.P.F.; Bassit, L.; Olmo, I.G.; Valiate, B.; Queiroz-Junior, C.M.; Pedrosa, C.; Ribeiro, F.M.; Guimarães, M.Z.; Rehen, S.; et al. 7-Deaza-7-fluoro-2’-C-methyladenosine inhibits Zika virus infection and viral-induced neuroinflammation. Antivir. Res. 2020, 180, 104855. [Google Scholar] [CrossRef]
  17. Sacramento, C.Q.; de Melo, G.R.; de Freitas, C.A.; Rocha, N.; Hoelz, L.V.B.; Miranda, M.; Fintelman-Rodrigues, N.; Marttorelli, A.; Ferreira, A.C.; Barbosa-Lima, G.; et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci. Rep. 2017, 7, 40920. [Google Scholar] [CrossRef]
  18. Bassetto, M.; Leyssen, P.; Neyts, J.; Yerukhimovich, M.M.; Frick, D.N.; Brancale, A. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication. Eur. J. Med. Chem. 2016, 123, 31–47. [Google Scholar] [CrossRef]
  19. Pattnaik, A.; Palermo, N.; Sahoo, B.R.; Yuan, Z.; Hu, D.; Annamalai, A.S.; Vu, H.; Correas, I.; Prathipati, P.K.; Destache, C.J.; et al. Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening. Antivir. Res. 2018, 151, 78–86. [Google Scholar] [CrossRef]
  20. Giancotti, G.; Rigo, I.; Pasqualetto, G.; Young, M.T.; Neyts, J.; Rocha-Pereira, J.; Brancale, A.; Ferla, S.; Bassetto, M. A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase. Sci. Rep. 2019, 9, 18413. [Google Scholar] [CrossRef] [Green Version]
  21. Eyer, L.; Nencka, R.; Huvarová, I.; Palus, M.; Joao Alves, M.; Gould, E.A.; De Clercq, E.; Růžek, D. Nucleoside inhibitors of Zika virus. J. Infect. Dis. 2016, 214, 707–711. [Google Scholar] [CrossRef] [Green Version]
  22. Zmurko, J.; Marques, R.E.; Schols, D.; Verbeken, E.; Kaptein, S.J.F.; Neyts, J. The Viral Polymerase Inhibitor 7-Deaza-2′-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Negl. Trop. Dis. 2016, 10, e0004695. [Google Scholar] [CrossRef]
  23. Slusarczyk, M.; Serpi, M.; Pertusati, F. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antivir. Chem. Chemother. 2018, 26, 2040206618775243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Furuta, Y.; Gowen, B.B.; Takahashi, K.; Shiraki, K.; Smee, D.F.; Barnard, D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 2013, 100, 446–454. [Google Scholar] [CrossRef] [Green Version]
  25. McGuigan, C.; Hinsinger, K.; Farleigh, L.; Pathirana, R.; Bugert, J.J. Novel Antiviral Activity of l-Dideoxy Bicyclic Nucleoside Analogues versus Vaccinia and Measles Viruses In Vitro. J. Med. Chem. 2013, 56, 1311–1322. [Google Scholar] [CrossRef]
  26. Suksanpaisan, L.; Susantad, T.; Smith, D.R. Characterization of dengue virus entry into HepG2 cells. J. Biomed. Sci. 2009, 16, 17. [Google Scholar] [CrossRef] [Green Version]
  27. Ke, P.-Y. The Multifaceted Roles of Autophagy in Flavivirus-Host Interactions. Int. J. Mol. Sci. 2018, 19, 3940. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Li, M.; Zhang, D.; Li, C.; Zheng, Z.; Fu, M.; Ni, F.; Liu, Y.; Du, T.; Wang, H.; Griffin, G.E.; et al. Characterization of Zika virus endocytic pathways in human glioblastoma cells. Front. Microbiol. 2020, 11, 242. [Google Scholar] [CrossRef]
  29. Huchting, J.; Winkler, M.; Nasser, H.; Meier, C. Synthesis of T-705-Ribonucleoside and T-705-Ribonucleotide and Studies of Chemical Stability. ChemMedChem 2017, 12, 652–659. [Google Scholar] [CrossRef]
  30. Vorbrüggen, H.; Bennua, B. Nucleoside syntheses, XXV1) A new simplified nucleoside synthesis. Chem. Ber. 1981, 114, 1279–1286. [Google Scholar] [CrossRef]
  31. Pierra, C.; Counor, C.; Storer, R.; Gosselin, G. Synthesis and antiviral evaluation of the 2’-C-methyl branched derivative of a nucleoside analog inhibitor of RNA viral infections, T-1106. Collect. Czech. Chem. Commun. 2011, 76, 1327–1333. [Google Scholar] [CrossRef]
  32. Reddy, P.G.; Chun, B.-K.; Zhang, H.-R.; Rachakonda, S.; Ross, B.S.; Sofia, M.J. Stereoselective Synthesis of PSI-352938: A β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyl-3′,5′-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV. J. Org. Chem. 2011, 76, 3782–3790. [Google Scholar] [CrossRef]
  33. Puig-de-la-Bellacasa, R.; Giménez, L.; Pettersson, S.; Pascual, R.; Gonzalo, E.; Esté, J.A.; Clotet, B.; Borrell, J.I.; Teixidó, J. Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. Eur. J. Med. Chem. 2012, 54, 159–174. [Google Scholar] [CrossRef]
  34. Beauchamp, L.M.; Serling, B.L.; Kelsey, J.E.; Biron, K.K.; Collins, P.; Selway, J.; Lin, J.-C.; Schaeffer, H.J. Effect of Acyclic Pyrimidines Related to 9-[(l,3-Dihydroxy-2-propoxy)methyl]guanine on Herpesviruses. J. Med. Chem. 1988, 31, 144–149. [Google Scholar] [CrossRef]
  35. Serpi, M.; Madela, K.; Pertusati, F.; Slusarczyk, M. Synthesis of phosphoramidate prodrugs: ProTide approach. Curr. Protoc. Nucleic Acid. Chem. 2013, 53, 15-5. [Google Scholar] [CrossRef]
  36. McGuigan, C.; Bugert, J.J.; Jones, A.; Pathirana, R.; Farleigh, L.E. Dideoxyribofuranosyl Pyrimidinones as Antiviral Agents. U.S. Patent Appllication US 20130012468 A1, 10 January 2013. [Google Scholar]
  37. McGuigan, C.; Serpi, M.; Slusarczyk, M.; Ferrari, V.; Pertusati, F.; Meneghesso, S.; Derudas, M.; Farleigh, L.; Zanetta, P.; Bugert, J. Anti-flavivirus Activity of Different Tritylated Pyrimidine and Purine Nucleoside Analogues. ChemistryOpen 2016, 5, 227–235. [Google Scholar] [CrossRef] [Green Version]
  38. Sherman, K.E.; Rouster, S.D.; Kong, L.X.; Aliota, M.T.; Blackard, J.T.; Dean, G.E. Zika virus replication and cytopathic effects in liver cells. PLoS ONE 2019, 14, e0214016. [Google Scholar] [CrossRef]
  39. Gobillot, T.A.; Humes, D.; Sharma, A.; Kikawa, C.; Overbaugh, J. The Robust Restriction of Zika Virus by Type-I Interferon in A549 Cells Varies by Viral Lineage and Is Not Determined by IFITM3. Viruses 2020, 12, 503. [Google Scholar] [CrossRef]
  40. Kim, J.A.; Seong, R.K.; Kumar, M.; Shin, O.S. Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models. Viruses 2018, 10, 72. [Google Scholar] [CrossRef] [Green Version]
  41. Zhu, Z.; Chu, H.; Wen, L.; Yuan, S.; Chik, K.K.; Yuen, T.; Yip, C.C.; Wang, D.; Zhou, J.; Yin, F.; et al. Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy. Int. J. Mol. Sci. 2019, 20, 392. [Google Scholar] [CrossRef] [Green Version]
  42. Ozdemir, A.; Ark, M. xCELLigence real time cell analysis system: A new method for cell proliferation and cytotoxicity. Niche 2013, 2, 15. [Google Scholar] [CrossRef]
Sample Availability: Samples of the compounds are not available from the authors.
Molecules 25 04813 g001 550
Figure 1. Chemical structures of nucleoside analogues 3a–3d and 4a–4o. The parent compounds 3a and 4a have been previously found to inhibit ZIKV replication in cell-based assays.
Figure 1. Chemical structures of nucleoside analogues 3a–3d and 4a–4o. The parent compounds 3a and 4a have been previously found to inhibit ZIKV replication in cell-based assays.
Molecules 25 04813 g001
Molecules 25 04813 g002 550
Figure 2. Chemical structures of nucleoside analogues 5a–5e. These molecules are currently being investigated in our group for their potential antiviral activity against different flaviviruses; the scaffold of 5a has been previously reported for its indirect antiviral properties against vaccinia and measles viruses.
Figure 2. Chemical structures of nucleoside analogues 5a–5e. These molecules are currently being investigated in our group for their potential antiviral activity against different flaviviruses; the scaffold of 5a has been previously reported for its indirect antiviral properties against vaccinia and measles viruses.
Molecules 25 04813 g002
Molecules 25 04813 sch001 550
Scheme 1. Preparation of nucleoside analogues 3b–3d and 4b–4o. Reagents and conditions: (i) a. BSA, MeCN, reflux, 1h; b. TMSOTf, MeCN, r.t., 2 h (66%); (ii) 25% MeONa/MeOH, 0 °C, 30 min (75%); (iii) a. BSA, MeCN, reflux, 1 h; b. SnCl4, r.t., 36 h (82%); (iv) 7N NH3/MeOH, r.t., o.n. (39% 4c, 25% 4g); (v) LiAlH(tBuO)3, an. THF, −20 °C, 3 h; (vi) Ac2O, DMAP, −20 °C, 2 h (99% over two steps); (vii) a. 4a, BSA, MeCN, reflux, 1h; b. SnCl4, 50 °C, 24 h (75%); (viii) 7N NH3/MeOH, r.t., o.n. (25% 4d, 46% 4h); (ix) a. BSA, MeCN, reflux, 1 h; b. SnCl4, r.t., o.n. (81%); (x) 25% MeONa/MeOH, 0 °C, 30 min (78%); (xi) dimethoxymethane, P2O5, CHCl3, 0 °C to r.t., 18 h (76%); (xii) PhCOONa, 15-Crown-5, DMF, reflux, 18 h (99%); (xiii) BF3*Et2O, Ac2O, 0 °C, 2 h (98%); (xiv) a. 4a, BSA, MeCN, reflux, 1 h; b. SnCl4, r.t., o.n. (80%); (xv) 7N NH3/MeOH, r.t., o.n. (69%); (xvi) NMI, THF, Pyr, r.t., o.n. (36–57%).
Scheme 1. Preparation of nucleoside analogues 3b–3d and 4b–4o. Reagents and conditions: (i) a. BSA, MeCN, reflux, 1h; b. TMSOTf, MeCN, r.t., 2 h (66%); (ii) 25% MeONa/MeOH, 0 °C, 30 min (75%); (iii) a. BSA, MeCN, reflux, 1 h; b. SnCl4, r.t., 36 h (82%); (iv) 7N NH3/MeOH, r.t., o.n. (39% 4c, 25% 4g); (v) LiAlH(tBuO)3, an. THF, −20 °C, 3 h; (vi) Ac2O, DMAP, −20 °C, 2 h (99% over two steps); (vii) a. 4a, BSA, MeCN, reflux, 1h; b. SnCl4, 50 °C, 24 h (75%); (viii) 7N NH3/MeOH, r.t., o.n. (25% 4d, 46% 4h); (ix) a. BSA, MeCN, reflux, 1 h; b. SnCl4, r.t., o.n. (81%); (x) 25% MeONa/MeOH, 0 °C, 30 min (78%); (xi) dimethoxymethane, P2O5, CHCl3, 0 °C to r.t., 18 h (76%); (xii) PhCOONa, 15-Crown-5, DMF, reflux, 18 h (99%); (xiii) BF3*Et2O, Ac2O, 0 °C, 2 h (98%); (xiv) a. 4a, BSA, MeCN, reflux, 1 h; b. SnCl4, r.t., o.n. (80%); (xv) 7N NH3/MeOH, r.t., o.n. (69%); (xvi) NMI, THF, Pyr, r.t., o.n. (36–57%).
Molecules 25 04813 sch001
Molecules 25 04813 sch002 550
Scheme 2. Preparation of nucleoside analogues 5a–5e. Reagents and conditions: (i) MsCl, Et3N, THF, rt, 18 h (97%); (ii) n-pentanol, NaH, THF, 70 °C, 24 h (71%); (iii) NC-NH2, NH4OH, MeOH, rt, 3 days (65%); (iv) methyl propiolate, EtOH, reflux, 3 h (70%); (v) AcBr, MeCN, reflux, 2 h (72%); (vi) Zn, glacial AcOH, EtOH, reflux, 2 h (55%); (vii) H2, Pd/C, MeOH, rt, 18 h (95%); (viii) a. I2, CAN, MECN, reflux, 6 h, b. MeONa, MeOH, rt, 18 h (56% over two steps); (ix) Pd(PPh3)4, CuI, DIPEA, DMF, rt, 18 h, then addition of Et3N, CuI, 80 °C, 8 h (28–55%); (x) a. MeNH2, MeOH, 60 °C, 6 h, b. p-TsCl, 1,4-dioxane, PhMe, reflux, 1 h (25% over two steps).
Scheme 2. Preparation of nucleoside analogues 5a–5e. Reagents and conditions: (i) MsCl, Et3N, THF, rt, 18 h (97%); (ii) n-pentanol, NaH, THF, 70 °C, 24 h (71%); (iii) NC-NH2, NH4OH, MeOH, rt, 3 days (65%); (iv) methyl propiolate, EtOH, reflux, 3 h (70%); (v) AcBr, MeCN, reflux, 2 h (72%); (vi) Zn, glacial AcOH, EtOH, reflux, 2 h (55%); (vii) H2, Pd/C, MeOH, rt, 18 h (95%); (viii) a. I2, CAN, MECN, reflux, 6 h, b. MeONa, MeOH, rt, 18 h (56% over two steps); (ix) Pd(PPh3)4, CuI, DIPEA, DMF, rt, 18 h, then addition of Et3N, CuI, 80 °C, 8 h (28–55%); (x) a. MeNH2, MeOH, 60 °C, 6 h, b. p-TsCl, 1,4-dioxane, PhMe, reflux, 1 h (25% over two steps).
Molecules 25 04813 sch002
Molecules 25 04813 g003 550
Figure 3. The effect of 3b (blue), 5a (purple), and a combination of both (light green) was tested at a concentration of 20 μm against ZIKV in A-549 cells plated in a 16 well CIM-Plate 16 using the xCELLigence RTCA DP Instrument. No compound (dark green; 0) and mock (no virus, pink) were used as controls. Dpi: days postinfection.
Figure 3. The effect of 3b (blue), 5a (purple), and a combination of both (light green) was tested at a concentration of 20 μm against ZIKV in A-549 cells plated in a 16 well CIM-Plate 16 using the xCELLigence RTCA DP Instrument. No compound (dark green; 0) and mock (no virus, pink) were used as controls. Dpi: days postinfection.
Molecules 25 04813 g003
Table
Table 1. Chemical structures of compounds 1a–1o and 2a–2m, previously reported non-nucleoside antiviral agents, selected for evaluation against ZIKV-induced cytopathic effect in relevant cellular models of the infection.
Table 1. Chemical structures of compounds 1a–1o and 2a–2m, previously reported non-nucleoside antiviral agents, selected for evaluation against ZIKV-induced cytopathic effect in relevant cellular models of the infection.
Molecules 25 04813 i001
CpdR1R2XR3ArAr1Ar2
1aC4H8N=CMe2,5-OH-Ph--
1bC4H8N=CMe2-OH-Ph--
1cC4H8N=CMePyrazine--
1dHHN=CMe2,5-OH-Ph--
1eC4H8N=CMe2-Pyridine--
1fC3H6N=CMe2-OH-Ph--
1gC4H8NHCO-2,5-OH-Ph--
1hC4H8NHCO-2,5-OH-Ph--
1iMeMeN=CMe2-OH-Ph--
1lC4H4N=CMe2-OH-Ph--
1mC4H4NHCO-2-Pyridine--
1nHHNHCO-2-Pyridine--
1oMeClNHCO-2-Pyridine--
2a--C=O--2-(3-Cl)-Benzo[b]thiophene2-Thiophene
2b--C=O--2-Benzo[b]thiophene2-Thiophene
2c--C=O--2-(3-CF3)-Benzo[b]thiophene2-Thiophene
2d--C=O--4-Me-Ph2-Thiophene
2e--C=O--2-(3-Cl)-Benzo[b]thiophene2-Furan
2f--C=O--2-(3-Cl)-Benzo[b]thiophenePh
2g--C=O--PhPh
2h--C=O--2-(3-Cl)-Benzo[b]thiophene2-Thiazole
2i--C=O--4-Me-PhPh
2l--SO2--Ph2-Thiophene
2m--C=O--Ph2-Thiazole
Table
Table 2. Reduction in ZIKV-induced cytopathic effect (CPE) and cytotoxicity data for the selected compounds at a fixed 10 μM concentration in multiple cell lines 1.
Table 2. Reduction in ZIKV-induced cytopathic effect (CPE) and cytotoxicity data for the selected compounds at a fixed 10 μM concentration in multiple cell lines 1.
Compound% Cell Viability, ZIKV–Infected HUH7% Cell Viability, HUH7 (Cytotoxicity)% Cell Viability, ZIKV–Infected Dbtrg% Cell Viability, Dbtrg (Cytotoxicity)% Cell Viability, ZIKV–Infected A459% Cell Viability, A459 (Cytotoxicity)
1a13.523.5015n.d.n.d.
1b3.414.5017.3n.d.n.d.
1c8.832018.4n.d.n.d.
1d8.320024.9n.d.n.d.
1e011.1014.1n.d.n.d.
1f4.915.3019.3n.d.n.d.
1g6.146.2024.3n.d.n.d.
1h5.426.1021.8n.d.n.d.
1i5.716.1015.5n.d.n.d.
1l12.122.0018.2n.d.n.d.
1m7.925.2012.6n.d.n.d.
1n5.137.9014.8n.d.n.d.
1o5.230.608.9n.d.n.d.
2a30.5 ± 15.9117.9 ± 42.2n.d.n.d.n.d.n.d.
2b25.5 ± 18.2107.4 ± 35.93.1 ± 3.994.9 ± 16.2n.d.n.d.
2c0.4 ± 0.7108.6 ± 55.94.1 ± 5.688.9 ± 18.5n.d.n.d.
2d4.5 ± 6.6119.5 ± 47.32.8 ± 2.876.9 ± 25.7n.d.n.d.
2e11.2 ± 9.9117.8 ± 40.90.25 ± 0.4380.5 ± 27.2n.d.n.d.
2f3.9 ± 1.975.7 ± 54.30.8 ± 1.476 ± 27.4n.d.n.d.
2g9.5 ± 7.1160.6 ± 50.60109.7 ± 4.8n.d.n.d.
2h9.8 ± 6.6134.9 ± 51.62.5 ± 2.2114.7 ± 4.5n.d.n.d.
2i4.5 ± 3.3106.4 ± 59.11.7 ± 1.796.7 ± 15.2n.d.n.d.
2l1.6 ± 3.6110.1 ± 63.59.2 ± 8.591.8 ± 14.5n.d.n.d.
2m3.3 ± 2.799.9 ± 62.911 ± 7.5104.2 ± 10.7n.d.n.d.
3a (2′-CMA)31.498.85.2107.340106.9
3b48.298.210.2100.533.6103.5
3c120.4 ± 80.3137.6 ± 35.653.3 ± 18.987.9 ± 18.7n.d.n.d.
3d101.5107.98.1115.559.6112.3
4a0.1100.64.697.4n.d.n.d.
4b0.1106.84.699.2n.d.n.d.
4c0.6118.57.3105.6n.d.n.d.
4d0105.60.498.7n.d.n.d.
4e090.8085.9n.d.n.d.
4f0.197.86.682.3n.d.n.d.
4g0.1117.50104.9n.d.n.d.
4h0106.50.199.3n.d.n.d.
4i0.2102.54.397.8n.d.n.d.
4l0101.34.598.5n.d.n.d.
4m0.2106.41.299.6n.d.n.d.
4n0.1104.92.298n.d.n.d.
4o0.197.86.682.3n.d.n.d.
5a50.3100.5075.7084.8
5b0110.15.7102.98.291.6
5c0104.43.994.7087.6
5d0.2104.30.474.528.6104.7
5e30.655.113.6522.781.6
Ribavirin61.1 ± 26.4158.7 ± 16.925.1 ± 10.194.8 ± 21.6n.d.n.d.
Control-DMSO100100100100100100
Control-ZIKV06 ± 1.4014.4 ± 4.300
The most interesting antiviral results obtained are highlighted in bold. 1 Reported values are the mean of at least 2 independent experiments, with standard deviations of ±10% of the value quoted unless otherwise stated (mean value ± standard deviations).
Table
Table 3. Antiviral EC50 and CC50 values calculated for selected hits in the HUH7 and U251 cell lines.
Table 3. Antiviral EC50 and CC50 values calculated for selected hits in the HUH7 and U251 cell lines.
CompoundEC50 a,c (μM), HUH7CC50 b,c (μM),
HUH7		SI d, HUH7EC50 a,c (μM), U251CC50 b,c (μM),
U251		SI d, U251
3b4 ± 0.2>20>5---
3c11.6 ± 1.3211.2 ± 4.618.28.2 ± 1.1203.7 ± 16.924.8
3d8.3 ± 0.9128.2 ± 21.115.48.6 ± 6.513.6 ± 1.71.6
5a10.2 ± 0.4>20>2---
Sofosbuvir5.8 ± 0.8133.5 ± 13.6237.7 ± 4.5139.1 ± 26.418
a EC50 = 50% effective concentration (concentration at which 50% inhibition of virus replication is observed). b CC50 = 50% cytostatic/cytotoxic concentration (concentration at which 50% adverse effect is observed on the host cell). c The EC50 and CC50 values are the mean of at least 3 independent experiments, with standard deviations of ±10% of the value quoted unless otherwise stated (mean value ± standard deviations). d SI = the ratio of CC50 to EC50.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Bassetto, M.; Cima, C.M.; Basso, M.; Salerno, M.; Schwarze, F.; Friese, D.; Bugert, J.J.; Brancale, A. Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections. Molecules 2020, 25, 4813. https://doi.org/10.3390/molecules25204813

AMA Style

Bassetto M, Cima CM, Basso M, Salerno M, Schwarze F, Friese D, Bugert JJ, Brancale A. Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections. Molecules. 2020; 25(20):4813. https://doi.org/10.3390/molecules25204813

Chicago/Turabian Style

Bassetto, Marcella, Cecilia M. Cima, Mattia Basso, Martina Salerno, Frank Schwarze, Daniela Friese, Joachim J. Bugert, and Andrea Brancale. 2020. "Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections" Molecules 25, no. 20: 4813. https://doi.org/10.3390/molecules25204813

Article Metrics

Back to TopTop